C1-Esterase Inhibitor

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Sep 1, 2008 → Dec 1, 2010

NCT ID

NCT00748202

About C1-Esterase Inhibitor

C1-Esterase Inhibitor is a phase 3 stage product being developed by CSL for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT00748202. Target conditions include Hereditary Angioedema.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Angioedema were approved

Approved (3) Terminated (0) Active (17)

✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved

✅GaradacimabCSLApproved

✅IdebenoneSanthera PharmaceuticalsApproved

🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02316353	Phase 3	Completed	Dec 31, 2014	Sep 21, 2017	Hereditary Angioedema Types I and II
NCT00748202	Phase 3	Completed	Sep 1, 2008	Dec 1, 2010	Hereditary Angioedema

Competing Products

20 competing products in Hereditary Angioedema

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	29
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	23
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	20
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	23
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	24
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	21
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Deferasirox FCT	Novartis	Phase 2	27
Canakinumab + Placebo	Novartis	Phase 3	40
Ilaris	Novartis	Pre-clinical	33
Standard of Care for Haemophilia A	Roche	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Tafamidis	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Phase 1	29